Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-151 |
Synonyms | |
Therapy Description |
ABBV-151 is a monoclonal antibody that targets the glycoprotein A repetitions predominant (GARP)-transforming growth factor beta 1 (TGFbeta1) complex, which prevents release of active TGF-beta1, potentially leading to antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-151 | ARGX-115|ABBV151|ABBV 151|ARGX 115|ARGX-115|ARGX115|Livmoniplimab | ABBV-151 is a monoclonal antibody that targets the glycoprotein A repetitions predominant (GARP)-transforming growth factor beta 1 (TGFbeta1) complex, which prevents release of active TGF-beta1, potentially leading to antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03821935 | Phase I | ABBV-151 ABBV-151 + Budigalimab | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | ISR | FRA | ESP | CAN | BEL | AUS | 4 |